/
MRKR
$1.46+$0.15 (+11.03%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$21.9M
17M shares
52-week range
$0.81 – $4.07
20% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
2.77%
Moderate
Price (6 mo)
Loading chart…
Change$-27.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $206.0K | $213.2K | $466.8K | $1.2M | $3.5M | $3.3M | $6.6M | $0 |
| Cost of revenue | $124.0M | $12.8M | $18.9M | $3.2M | $12.0M | $10.4M | $13.5M | $0 |
| Gross profit | −$123.8M | −$12.6M | −$18.4M | −$1.9M | −$8.5M | −$7.1M | −$6.9M | $0 |
| Gross margin | -60095.0% | -5887.4% | -3944.9% | -154.7% | -240.6% | -214.6% | -104.3% | — |
| R&D | $124.0M | $12.8M | $18.9M | $27.8M | $12.0M | $10.4M | $13.5M | $11.8M |
| Operating income | −$148.2M | −$22.5M | −$28.9M | −$39.5M | −$19.8M | −$14.6M | −$11.1M | −$12.9M |
| EBITDA | −$148.0M | −$22.4M | −$27.6M | −$38.7M | −$17.0M | −$11.3M | −$10.7M | −$12.4M |
| Net income | −$148.0M | −$21.4M | −$28.7M | −$41.9M | −$29.9M | −$8.2M | −$10.7M | −$12.2M |
| Net margin | -71826.4% | -10050.9% | -6149.7% | -3372.7% | -851.9% | -248.8% | -162.8% | — |
| EPS (diluted) | -77.50 | -4.70 | -6.10 | -5.47 | -3.58 | -1.93 | -1.19 | -0.79 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-0.96 | $-1.24–$-0.68 | 2 |
| 2027 | $20M | $-1.01 | $-1.08–$-0.94 | 2 |
| 2028 | $84M | $0.47 | $-1.02–$1.44 | 3 |
| 2029 | $164M | $1.97 | $0.21–$3.55 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.08
Price
$1.46
Implied downside
-26%
Peer comparison
Marker Therapeutics, Inc. Common Stock
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
www.markertherapeutics.com- Employees
- 5
- IPO / List date
- Jan 7, 1998
- HQ
- HOUSTON, TX
Held by traders on TradeandTell
No one on the platform currently holds MRKR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 175,294 | $227.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-01-27 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded MRKR yet.
